S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Asian stocks track Wall Street's decline as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
NYSE:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

$9.25
-0.11 (-1.18%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$9.08
$9.39
50-Day Range
$9.09
$12.90
52-Week Range
$6.01
$13.14
Volume
626,100 shs
Average Volume
564,873 shs
Market Capitalization
$652.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Zymeworks MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
62.2% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.06mentions of Zymeworks in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to ($0.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.92 out of 5 stars

Medical Sector

842nd out of 929 stocks

Pharmaceutical Preparations Industry

384th out of 418 stocks

ZYME stock logo

About Zymeworks Stock (NYSE:ZYME)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

ZYME Stock Price History

ZYME Stock News Headlines

The next wave of AI domination is emerging. The most explosive gains could come from these 4 stocks
2024 could be a challenging year. AI will continue creating profit opportunities (in some surprising new ways), but global conflict, divisive politics and not-yet-tamed inflation could bring uncertainty.
The next wave of AI domination is emerging. The most explosive gains could come from these 4 stocks
2024 could be a challenging year. AI will continue creating profit opportunities (in some surprising new ways), but global conflict, divisive politics and not-yet-tamed inflation could bring uncertainty.
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Zymeworks Q4 2023 Earnings Preview
ZYME Apr 2024 7.500 call
ZYME Oct 2024 15.000 call
ZYME Mar 2024 20.000 call
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/15/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:ZYME
Employees
272
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+62.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-118,670,000.00
Net Margins
-156.12%
Pretax Margin
-156.87%

Debt

Sales & Book Value

Annual Sales
$76.01 million
Book Value
$6.63 per share

Miscellaneous

Free Float
69,707,000
Market Cap
$652.77 million
Optionable
Optionable
Beta
1.14
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 61)
    CEO & Chairman of the Board
    Comp: $1.04M
  • Dr. Christopher Astle Ph.D. (Age 43)
    Senior VP & CFO
    Comp: $682.22k
  • Dr. Paul Moore Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $872.67k
  • Mr. Mark Hollywood (Age 54)
    Executive VP and Head of Technical & Manufacturing Operations
  • Mr. Daniel Dex J.D.
    Ph.D., Senior VP, Corporate Secretary & General Counsel
  • Diana Papove
    Senior Manager of Corporate Communications
  • Dr. Lindsey Foulkes B.Sc.
    Ph.D., Vice President of Corporate Development
  • Ms. Laura O'Connor
    Vice President of Human Resources & DEI
  • Dr. Jeffrey Smith M.D.
    Executive VP & Chief Medical Officer
  • Dr. Josemund Menezes MBBS
    Managing Director of Early-Stage Development for Asia Pacific

ZYME Stock Analysis - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price target for 2024?

1 equities research analysts have issued 12 month price objectives for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2024?

Zymeworks' stock was trading at $10.39 at the beginning of the year. Since then, ZYME stock has decreased by 11.0% and is now trading at $9.25.
View the best growth stocks for 2024 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZYME earnings forecast
.

How can I listen to Zymeworks' earnings call?

Zymeworks will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) issued its earnings results on Wednesday, March, 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.19. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative trailing twelve-month return on equity of 26.20% and a negative net margin of 156.12%.

What ETF holds Zymeworks' stock?

Invesco Russell 2000 Dynamic Multifactor ETF holds 165,345 shares of ZYME stock, representing 0.41% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ZYME) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners